NGENF News and Press, NervGen Pharma Corp From 11/16/22

Canada's NervGen Pharma ( OTCQX:NGENF ) said it granted 400K incentive stock options to its directors. The stock options are exercisable at a price of C$1.74 per share for five years. The company noted all options were granted in accordance with the policies of the TSX...

Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal females U.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to...

Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...

Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has en...

Dose(s) to be tested in bridging cohorts of males and premenopausal females resulted in significant functional improvements in animal models of nervous system damage NervGen has completed enrollment of third and final multiple ascending dose cohort of postmenopausal women Vancouver, Br...

AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETING EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage ...

NervGen Pharma ( OTCQX:NGENF ) has been awarded up to $1.5M in US Department of Defense funding from the Military Operational Medicine Research Program to evaluate NervGen's NVG-291-R as a therapeutic to enable accelerated and enhanced restoration of function following periph...

The $1.5 million award is to evaluate the ability of NervGen's NVG-291-R to accelerate and enhance restoration of function following peripheral nerve injury (PNI) The research is to support a potential game changing therapeutic approach to restore function for US military service members and...

Summary NervGen is a Canadian early-stage biotech company with unprecedented preclinical work in spinal cord injury and multiple sclerosis. The company is finalizing a Phase 1 clinical trial for its ‘pipeline in a product’ NVG-291 to assess safety, tolerability and m...

Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Direct...